Back to Search
Start Over
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
- Source :
- OncoImmunology, Vol 10, Iss 1 (2021)
- Publication Year :
- 2021
- Publisher :
- Taylor & Francis Group, 2021.
-
Abstract
- Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib may act through off-target effects. However, we found that low-dose of ALK inhibitors, crizotinib and ceritinib, may stimulate ICD in anaplastic large cell lymphoma, in which ALK is activated due to a chromosomal translocation, suggesting on target ICD-promoting effects.
Details
- Language :
- English
- ISSN :
- 2162402X
- Volume :
- 10
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- OncoImmunology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.23c9a7cc4f4489bbcbe3bcb80d2149b
- Document Type :
- article
- Full Text :
- https://doi.org/10.1080/2162402X.2021.1973197